

From: Cagungun, Nannette  
Sent: Tuesday, June 28, 2016 10:48 AM  
To: 'jcastillo@Portola.com'  
Subject: Information Request

Our Reference: BL 125586/0

Dear Ms. Castillo:

We are reviewing your December 17, 2015 biologics license application (BLA) for Coagulation Factor Xa (Recombinant), Inactivated, and have the following request regarding the release specification for Polysorbate 80:

1. On April 20, 2016, you indicated that you are developing a method for the detection and quantitation of Polysorbate 80 in andexanet alfa. In addition to our request for sucrose and mannitol, submitted on 22 June 2016, please include acceptance limits for Polysorbate 80 in the drug product specification by August 1, 2016, and commit to completing the method validation by October 31, 2016 and re-evaluate the acceptance limits after you have obtained data from 20 batches of drug product or one year post licensure, whichever comes first.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your response to this information request as an amendment to this file by July 8, 2016 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

The action due date for this file is August 17, 2016.

If you have any questions, please contact LT Maruna at (240) 402-8454.

Sincerely,

Nannette Cagungun, MS, PD, RAC  
Regulatory Project Manager  
OBRR/CBER/FDA  
10903 New Hampshire Ave  
WO71-4258  
Silver Spring, MD 20993-0002  
Tel: (240) 402-8267

Fax: (301) 595-1128

Email: [nannette.cagungun@fda.hhs.gov](mailto:nannette.cagungun@fda.hhs.gov)

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS  
ADDRESSED AND MAY CONTAIN

INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM  
DISCLOSURE UNDER LAW. If you are

not the addressee, or a person authorized to deliver the document to the  
addressee, you are hereby notified that any

review, disclosure, dissemination, copying, or other action based on the  
content of this communication is not authorized. If

you have received this document in error, please immediately notify the  
sender immediately by e-mail or phone.